Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fostamatinib + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fostamatinib | Tavalisse | R788|R935788 | SYK Inhibitor 15 | Fostamatinib (R788) binds and inhibits Syk kinase thus interfering with mast cell, macrophage, and B-cell activation as well as downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis (NCI Drug Dictionary). |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03246074 | Phase I | Fostamatinib + Paclitaxel | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Completed | USA | 0 |